| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.2 | 1.2 |
| Profit before tax | -6.7 | -10.4 |
| Net income | -6.7 | -10.4 |
| EPS (diluted, $ a share) | $-0.03 | $-0.10 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -0.7% |
|---|
10-Q filed with the SEC, NASDAQ: LUCD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lucid Diagnostics Inc.: key numbers
- Share price
- $0.3978Close, Nov 16
- Market cap
- $82.3M
- Shares outstanding
- 206.98MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lucid Diagnostics Inc.
All →Lucid Diagnostics Financial Results
Lucid Diagnostics reported third quarter 2026 financial results, highlighting the commencement of Medicare reimbursement for its EsoGuard Esophageal DNA Test at a rate of $1,938.01 per test. The company performed 2,871 tests during the quarter and reported record monthly test volume in October following the Medicare coverage milestone.
“Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test. This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”
Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer
“Our pursuit of EsoGuard’s enormous clinical and commercial opportunity is now substantially less constrained by external factors. Lucid’s near-term growth now depends almost entirely on our team’s commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint.”
Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer
Lucid Diagnostics Capital Raise of $15M
Lucid Diagnostics entered into subscription agreements with accredited investors for the private placement of 15,000 shares of newly designated Series C Convertible Preferred Stock. The offering generated aggregate gross proceeds of approximately $15.0 million at a purchase price of $1,000 per share.
- Value
- $15M
Lucid Diagnostics Nasdaq/NYSE Compliance Notice
Lucid Diagnostics Inc. received a deficiency notice from Nasdaq on October 12, 2026, because its common stock closing bid price fell below the $1.00 minimum requirement for 30 consecutive business days. The company has 180 calendar days, until April 12, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days.
- Counterparty
- Nasdaq
- Term
- 180 days
Lucid Diagnostics Business Update
Lucid Diagnostics announced progress across three regulatory and reimbursement pathways for its EsoGuard and EsoCheck products, including a Medicare Advisory Panel recommendation to maintain its current payment basis. Additionally, the AMA approved a new Category III CPT code for EsoCheck procedures, and the CDC/NCHS is considering a new ICD-10-CM diagnosis code for positive EsoGuard results. These administrative milestones are intended to streamline billing, coding, and physician reporting for the company's esophageal cancer screening tools.